- 2020
- September-The first patient successfully dosed with the candidate drug SR419
- 2019
- July-SIMR initiated the first-in-human study of candidate drug SR419 for peripheral neuropathic pain
- 2018
- November - Received over 100 million RMB for A round of financing
- May - The SPF animal facilities passed the on-site audit
- 2017
- May - SIMR received financial support from the Smart Manufacturing Industry in Lingang
- 2016
- November - Received over ten millions RMB for Pre-A round of financing
- SIMR was granted as one of the "50 Best Startups with Highest Investment Potential in Shanghai"
- 2015
- June-SIMR was supported by the 2015 Shanghai SME Innovation Fund
- 2014
- March 6 - Shanghai SIMR Biotechnology Co., Ltd. was established in Shanghai
